Abstract
Prophylactic application of clotting factor concentrates is the basis of modern treatment of severe haemophilia A. In children the early start of prophylaxis as primary or secondary prophylaxis has become the gold standard in most countries with adequate resources. In adults prophylaxis is reasonably continued when started as primary or secondary prophylaxis in childhood to maintain healthy joint function.
Initial data support that adult patients with already existing advanced joint arthropathy benefit from tertiary prophylaxis with significantly lowered number of bleeds, almost absence of target joints and less time off work. Current prophylactic regimens, although very effective, do not completely prevent joint disease in a long-term perspective. Joint arthropathy in primary prophylaxis develops over many years, sometimes over a decade or even longer time periods. The ankle joints are the first and most severely affected joints in those patients and thus may serve in outcome assessment as an indicator of early joint arthropathy when followed by ultrasound or MRI. Optimized outcome and best utilisation of available resources is expected from individualization of therapy regimens which comprises the individual's bleeding pattern, the condition of the musculoskeletal system, level of physical activity and the pharmacokinetik profile of substituted coagulation factor, and most recently includes novel products with extended half-lives.
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Prophylaxis in Haemophilia
The key to a successful long-term outcome in patients with haemophilia is an efficient prophylaxis that prevents bleeding in joints for children and adults with haemophilia.
Efficient prophylaxis requires taking into account the available resources (clotting factor concentrate, trough levels), the bleeding trigger (activity levels, chronic synovitis, already existing arthropathy) and most importantly the number of acceptable bleeds, especially joint bleeds (Fig. 1) . Depending on the available resources, the treatment objectives can vary between countries and treatment centers. In an almost ideal setting, the number of spontaneous bleeds should be minimized in order to prevent the manifestation of joint arthropathy. The severity of joint arthropathy mirrors as a kind of cumulative memory the number of experienced joint bleed and, thus, reflects the overall quality of the prophylactic treatment regimen.
Once joint damage has occurred, it will progress over the patient's life time even if no further bleeds occurs in the affected joints Objectives in those patients include slowing down progression of joint disease, reducing pain and inflammation and maintaining mobility, especially in adult haemophiliacs with already advanced joint disease.
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Current approaches improving prophylaxis outcome include available resources, individualisation of treatment regimens with respect to dose, intervals and type of concentrate, considering trough levels and bleeding triggers in the respective patients.
Initiation of prophylaxis in young children
Prophylaxis in children is most efficient when started at an early age. Prophylaxis initiated before the age of 2 years 3 resulted in a better outcome than prophylaxis commenced at age 3-5 years or 6-9 years 4, 5 . National guidelines and recommendations in several European countries advise starting prophylaxis early 6, 7 .
In the last decade, several studies suggest beginning with a once-weekly regimen [8] [9] [10] .
The rationale behind this is either to avoid the placement of central venous access devices and to account for the different clinical presentations, thus tailoring therapy and optimizing cost-effectiveness 8, 9 or to lower the risk of inhibitor formation 10 . The
Canadian primary prophylaxis experience begins with a once-weekly regimen (50 U/kg BW), that, depending on number of bleeds, is intensified in a first step to twiceweekly treatment (2 times 30 U/kg BW) and, in a third step, to every-other-day therapy (25 IU/kg BW) 11 . Median ages at switching to steps 2 and 3 were 4.1 and 9.7 years, respectively. Twenty percent of the patients remained on the lowest regimen during the observation time of this study. For this regimen, switches depend on the number of bleeds. Long-term follow-up observation of this cohort is needed, in order to assess whether this regimen is still effective against late onset of arthropathy. Challenge (EPIC) study. However, the EPIC study was stopped after inclusion of only 19 patients because of unexpected high incidence of inhibitors. The reasons given for stopping the study were difficulties in adherence to the complex protocol in a multinational, multicenter study setting and an increasingly unrealistic perpective to achieve a significantly lower inhibitor frequency within this study 14 . 
Dynamics of developing joint arthropathy

The ankle joint as arthropathy indicator
Before the era of prophylaxis, e.g. in the 1970s, knee joint bleeds were the most frequently noted joint bleeds and knees were the clinically leading joint in most patients 21 . With the beginning of the era of prophylaxis, the knee joint, as a musclecontrolled joint, became more stable and the ankle joints became the first joints to be affected and, thus, represent the clinically most indicative joint. Oldenburg et al. Ours and other authors' studies indicate that imaging score-based diagnosis of arthropathy is possible long before being revealed by clinical scores 5 . However, plain X-ray is too insensitive to diagnose early joint pathology, making it inappropriate to diagnose early joint damage. Ankles, as the first affected joints for the majority of patients, offer an interesting opportunity for diagnosing early joint disease and subsequent adapting clinical decisions.
Outcome assessment
Prophylaxis has greatly improved joint health and is challenging joint outcome assessment. Because of the low number of about one joint bleed every 2 years resulting from intensive prophylaxis programs 5, 19, 20 , clinical manifestation of joint disease has become a subtle process, starting mildly, subclinically and progressing slowly over years. Thus, diagnosing early joint disease and taking timely and adequate action has become difficult.
Outcome assessment comprises several tools including annual bleed rates, physical joint examination, imaging measures such as plain X-rays, MRI and ultrasound assessment. Quality-of-life questionnaries complement the instrumentarium for outcome assessment (Blanchette et al. 2014 27 
Prophylaxis in adult patients
While primary prophylaxis irepresents the gold standard for preserving joint function in children with severe haemophilia, prophylaxis in adult patients is still debated.
There are two groups of adult patients which have to be addressed seperately. The first group of patients includes those who started primary or secondary prophylaxis early in their life and maintained a good joint health into adulthood. A small number of published studies suggest that these patients benefit from a life long prophylaxis 16, [18] [19] [20] . These studies reported a follow up of 12-30 years and demonstrated that haemophilia patients with an ongoing prophylaxis regimen present with wellpreserved joint function and only mild joint arthropathy at the age of 30-40 years [18] [19] [20] .
The patients from the Netherlands with an intermediate dosage regimen had a slightly worse outcome at the age of 30 years than Swedish patients with a high dose prophylaxis regimen 19 . In the German cohort, 90% of patients showed some, mostly mild arthropathy, mainly in their ankle joints after a 26 year follow-up 20 . There are several reports that a proportion of young adults switch to an on-demand and that
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From some of these patients stay on this regimen with only few bleeding and little joint arthropathy 44, 45 . However, no follow-up data are available that report joint condition of these patients at the age of 40-50 years or older. As initial joint damage always progresses, even in the absence of joint bleeds, a worsening of joint disease can be anticipated. The joint annual bleed rate might serve as a surrogate for switching those patients back to a prophylactic regimen. The joint ABR should not be higher than during an intensive prophylaxis regimen, which is about 1-2 joint bleeds within two years. These results indicate that also adults with already established severe joint arthropathy benefit from a prophylactic regimen in terms of number of bleeds, presence of target joints, mobility and time off work. However, long-term follow-up studies are needed to substantiate these effects.
Individualising of treatment regimens
.Individualisation of therapy would not be an issue if the trough factor levels could be 1 0 raised in every patient to 15-20%, thus allowing an almost bleed-free life. However, resources are limited and individualisation is applied to get the best outome with the given resources. On an economic basis, individualization also implicates that a certain risk of bleeding is taken. An individualised regimen comprises the individual's bleeding pattern, the condition of the musculoskeletal system, level and timing of physical activity and actual levels as well as trough levels of coagulation factor 47 .
Individual bleeding risk -more than factor levels
A subset of 10 to 15% of patients with severe hemophilia A exhibits a mitigated disease phenotype, with significantly reduced frequencies of spontaneous bleeding and lower consumption of factor concentrates 48 . This clinical heterogeneity is also reflected by the late onset of the first joint bleed and furthermore in development of only minimal arthropathy. This mitigated clinical phenotype is chiefly determined by the underlying mutations in the F8/F9 genes 49, 50 . Especially missense mutations, splice site mutations outside conserved regions and small deletions within A series were associated with less bleeding 51 . Furthermore, the inflammatory response to the presence of blood in a joint varies, which is believed to be in part dependent on genetic variations in the genes involved in the inflammatory and immune regulatory pathways [52] [53] [54] . This variation may influence the subsequent developement of chronic synovitis and ultimately also of joint arthropathy. Indeed, the Joint Outcome Study reported several boys with multiple episodes of hemarthrosis who remained free of joint damage. Other patients showed joint damage in the absence of clinical bleeds 5 .
In patients with greater number of bleeds or with a stronger infammatory response to a bleed larger factor doses and more frequent application are required to prevent the onset of joint disease.
Pharmacokinetic variation in patients and new products
Collins et al. demonstrated a great variation of pharmacokinetics dependent on age (shorter half life in young children than in adults) but also within patient groups of the same age, where he found an almost 100% difference in time-to-trough levels of > 1% after application of a standardised FVIII dose 55 . Several studies have shown that the level of the von Willebrand factor has a major influence on the factor VIII halflife [56] [57] [58] . Higher VWF levels correlate with increasing intervals of FVIII substitutions 57, 58 . Therefore, assessment of the patient's individual pharmacokinetic 1 1
profile is regarded as important for individualisation of therapy. Since, a classical pharmacokinetic profile is based on numerous blood draws over two or more days, population pharmacokinetics presents an elegant approach to assess the pharmacokinetic profile by routine factor level measurements at regular visits in the treatment center 59, 60 . Population phamacokonetics will become an important measure for individualised treatment regimens 60 .
A number of new factor concentrates and drugs based on other technologies with improved half-lives and alternative administration routes will soon be available . On the horizon are novel products applying new technologies such as a bispecific antibody that mimics factor VIII 61, 62 . This product has the potential to almost eliminate bleeds by weekly subcutaneous injections of the bispecific antibody 63 .
Prophylaxis in Haemophilia B
There is an ongoing discussion whether the phenotypes of haemophilia A and Although these data refer to a very early stage of treatment, decisions on the prophylactic treatment are made at this time and are based on criteria as the onset of bleeds, especially joint bleeds. Therefore it appears safe to follow the same principles for prophylaxis in haemophilia B patients as it has been outlined in this review for Haemophilia A patients. Anyway the longer half life of factor IX and especially the new recombinant factor IX products with extended half-lives of up to 100 hours will make a difference in the prophylactic regimens.
Conclusion
In conclusion, current therapy regimens include early start of prophylaxis as primary or secondary prophylaxis. Prophylaxis is increasingly regarded as a life-long therapy, also applied as tertiary prophylaxis in adults with already existing arthropathy. There (2013) 20 , that underline that progression of joint arthropathy during intensive prophylaxis regimens is a process with subtle progression over years. PS=Petterson Score, GS=Gilbert Score. Scores equal or greater 2 are regarded to be pathological.
The ankle joints are the first joints which develop arthropathy after a median time of 
